CI at a glance
Cigna (CI, SEC CIK 1739940) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on July 30, 2026, an 8-K current report on September 30, 2026 and Form 4 insider filings as recently as September 8, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Cigna (CI) reported revenue of $274.9 billion (up 11.2% from FY2024) and net income of $6.0 billion. Diluted EPS was $22.18.
- As of June 30, 2026, 49 institutional investment managers tracked by SignalX reported holding Cigna (CI) shares worth $28.5 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Neville Everett on September 3, 2026 of 617 shares at $284.05 per share.
- In the last 90 days, CI insiders reported 0 open-market purchases ($0) and 3 open-market sales ($6.3M) on Form 4, a net sale of $6.3M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $274.9B
- +11.2% vs prior year
- Insiders · 90 days
- 0 buys · 3 sells
- Net −$6.3M
- 13F holders
- 49 funds
- $28.5B · +0 vs prior quarter
- Latest 8-K
- Sep 30, 2026
- Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Management Discussion & Analysis
- Revenue $274.9B, up $27.8B (+11%) YoY; pharmacy revenues dominant driver, up $31.3B (+17%) from Evernorth customer growth
- Evernorth (best segment): adjusted revenues $235B, pre-tax margin 3.1% vs 3.5%; Cigna Healthcare (worst): revenues down 11% to $47.2B, MCR 84.4% vs 83.2%
- Consolidated adjusted income from operations $8.0B vs $7.7B; Cigna Healthcare pre-tax margin 8.8% vs 8.0%; shareholders' net income $6.0B vs $3.4B (+73%)
- Operating cash flow $9.6B vs $10.4B; capex $1.2B vs $1.4B; buybacks $3.6B (11.9M shares) vs $7.0B (20.9M shares); HCSC divestiture generated $4.9B proceeds
- Key risks: rebate-free pharmacy model transition costs to pressure Evernorth near-term; strategic optimization program costs $749M pre-tax in 2025 with further charges anticipated; $1.3B capex guided for 2026
Risk Factors
- FTC administrative complaint against Express Scripts (Sept 2024) for anticompetitive insulin rebate practices; settled Feb 2026 with no penalty but required business practice changes
- Total indebtedness ~$31.5B as of Dec 31, 2025, representing significant leverage constraining capital allocation flexibility
- Top 10 retail pharmacy chains represent ~47% of largest network; contracts nonexclusive and terminable on short notice
- Goodwill and intangibles ~$73.5B (47% of total consolidated assets); VillageMD investment fully impaired, $2.7B loss recorded in 2024
- AI litigation active: lawsuit claiming improper use of AI in claims evaluation process; generative AI risks flagged as unquantifiable regulatory exposure
Business Overview
- Global health company operating two core segments: Evernorth Health Services (PBM/specialty pharmacy) and Cigna Healthcare (medical benefits), serving 185M+ customer relationships across 30+ markets
- Completed sale of Medicare Advantage, Medicare Part D, and CareAllies businesses to HCSC on March 19, 2025: major portfolio exit, marking deliberate retreat from government-sponsored individual Medicare market
- Announced transformative rebate-free pharmacy benefits model: upfront drug discounts passed directly to customers; Cigna Healthcare fully insured adoption in 2027, becoming standard Evernorth client offering in 2028
- Launched EnGuide Pharmacy in 2025, dedicated GLP-1 medication pharmacy with clinical support, operating two licensed pharmacies including one fulfillment facility in Ohio: direct response to surging demand for GLP-1 drugs
- Single PBM client (Centene) drove ~19% of total external revenue in 2025, up from 16% in 2024: significant and growing revenue concentration risk
AI summary of the CI 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- No risk-factors section provided; supplied text covers equity repurchases, insider trading plans, exhibits, and signatures only
AI summary of the CI 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item EX-99.1: Item EX-99.1
- Reaffirms 2026 guidance: adjusted revenue ~$280B, adjusted EPS at least $30.45, medical care ratio 83.7%-84.7%
- Sets 2030 target of 10%-14% adjusted EPS CAGR and ~$50B cumulative operating cash flow
Item 7.01: Regulation FD Disclosure
- 2026 outlook reaffirmed: adjusted revenue approximately $280B and adjusted EPS at least $30.45
- Evernorth adjusted operating income target at least $6.9B
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for the three months ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing the detailed financial results
Item EX-99.1: Item EX-99.1
- Q2 revenue rose 7% to $71.7B; adjusted operating income increased 6% to $2.1B, signaling solid execution
- Adjusted EPS reached $7.78 versus $7.20, while GAAP EPS increased to $6.29 from $5.71
Item 7.01: Regulation FD Disclosure
- 2026 adjusted operating income outlook reaffirmed at least $30.35 per share
- No change to previously issued guidance, reducing near-term earnings-surprise risk
AI summaries of CI 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CI
Don't miss the next CI filing
- Alerts as it files. A push when CI files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CI, by share count.
- Ask anything. An AI agent that reads every CI filing and answers with sources.
CI alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Neville Everett | Sell | Sep 3, 2026 | 617 | $284.05 |
| Evanko Brian C | A | Sep 1, 2026 | 6,716 | - |
| Evanko Brian C | A | Sep 1, 2026 | 3,113 | - |
| Kurian George | A | Aug 31, 2026 | 108.664 | $276.08 |
| Jones Nicole S | Sell | Aug 18, 2026 | 2,677 | $279.61 |
| Holgerson Bryan | A | Aug 6, 2026 | 0.984 | $275.25 |
| Jones Nicole S | M | Aug 5, 2026 | 1,301 | $192.02 |
| Jones Nicole S | M | Aug 5, 2026 | 1,301 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $195.3B | $247.1B | $274.9B |
| Operating Income | $8.5B | $9.4B | $9.2B |
| Net Income | $5.2B | $3.4B | $6.0B |
| Op. Margin | 4.4% | 3.8% | 3.3% |
| Net Margin | 2.6% | 1.4% | 2.2% |
| Balance Sheet | |||
| Total Assets | $152.8B | $155.9B | $157.9B |
| Equity | - | $41.0B | $41.7B |
| ROE | - | 8.4% | 14.3% |
| Per Share | |||
| EPS | $17.39 | $12.12 | $22.18 |
| Cash Flow | |||
| Operating CF | $11.8B | $10.4B | $9.6B |
Source: XBRL data in Cigna (CI)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate CI share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 49 | $28.54B |
| Q1 2026 | 49 | $28.38B |
| Q4 2025 | 47 | $30.80B |
| Q3 2025 | 50 | $35.38B |
| Q2 2025 | 50 | $38.83B |
| Q1 2025 | 47 | $28.54B |
| Q4 2024 | 41 | $19.95B |
| Q3 2024 | 38 | $11.54B |
- Two Sigma Investments+1.17M (+183%)
- BlackRock+840.1K (+4%)
- State Street Corp+399.1K (+3%)
- Millennium Management+330.1K (+263%)
- Morgan Stanley+258.0K (+8%)
- FMR LLC (Fidelity)−2.94M (-27%)
- T. Rowe Price Group−1.31M (-51%)
- AQR Capital Management−1.15M (-44%)
- JPMorgan Chase & Co−611.3K (-11%)
- Franklin Resources−354.9K (-45%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 371 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CI filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Sep 30, 2026 | - | Analysis | - |
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 2, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 6, 2026 | - | - | - |
| 10-Q | Jul 30, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 4 | Jun 16, 2026 | - | - | - |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 2, 2026 | - | - | |
| 4 | May 14, 2026 | - | - | |
| 8-K | May 13, 2026 | - | Analysis | |
| 8-K | Apr 30, 2026 | - | Analysis | - |
| 10-Q | Apr 30, 2026 | Mar 31, 2026 | Analysis | |
| SC 13G | Apr 29, 2026 | - | - | |
| 8-K | Apr 27, 2026 | - | Analysis | - |
| 4 | Apr 24, 2026 | - | - | - |
| 4 | Apr 24, 2026 | - | - | - |
| 4 | Apr 24, 2026 | - | - | - |
| 4 | Apr 24, 2026 | - | - | - |
| 4 | Apr 24, 2026 | - | - | - |
| 4 | Apr 24, 2026 | - | - | - |
| 4 | Apr 24, 2026 | - | - | - |
Related Health Care companies
- ALHC · Alignment Healthcare, Inc.Hospital & Medical Service Plans
- CNC · Centene CorporationHospital & Medical Service Plans
- CLOV · CLOVER HEALTH INVESTMENTS, CORP. /DEHospital & Medical Service Plans
- ELV · Elevance HealthHospital & Medical Service Plans
- HUM · HumanaHospital & Medical Service Plans
- MOH · Molina HealthcareHospital & Medical Service Plans
- OSCR · Oscar Health, Inc.Hospital & Medical Service Plans
- TRUP · TRUPANION, INC.Hospital & Medical Service Plans
CI SEC filings: frequently asked questions
Are CI insiders buying or selling?
In the last 90 days, Cigna (CI) officers, directors and 10% owners reported no open-market purchases and 3 open-market sales worth $6.3 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CI stock?
As of June 30, 2026, the largest Cigna (CI) holders among the 13F filers tracked by SignalX were BlackRock ($6.5 billion), Vanguard Capital Management LLC ($4.8 billion), State Street Corp ($3.5 billion), FMR LLC (Fidelity) ($2.2 billion), Vanguard Portfolio Management LLC ($1.7 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CI's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Cigna (CI) reported revenue of $274.9 billion (up 11.2% from FY2024) and net income of $6.0 billion. Diluted EPS was $22.18. The figures come from the XBRL data in the 10-K.
What are the main risks in CI's latest 10-K?
In the 10-K filed February 26, 2026, Cigna (CI) flagged: FTC administrative complaint against Express Scripts (Sept 2024) for anticompetitive insulin rebate practices; settled Feb 2026 with no penalty but required business practice changes. Total indebtedness ~$31.5B as of Dec 31, 2025, representing significant leverage constraining capital allocation flexibility. (AI summary of the Risk Factors section.)
What did CI report in its latest 8-K?
Cigna (CI) filed an 8-K on September 30, 2026 reporting Item 7.01 (Regulation FD Disclosure). Reaffirms 2026 guidance: adjusted revenue ~$280B, adjusted EPS at least $30.45, medical care ratio 83.7%-84.7%.
What are the latest CI SEC filings?
Cigna (CI) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on July 30, 2026, an 8-K current report on September 30, 2026 and a Form 4 insider filing on September 8, 2026.
What is CI's SEC CIK number?
Cigna (CI)'s SEC Central Index Key (CIK) is 1739940. EDGAR lists every CI filing under that number.
Ask anything about CI
The research agent reads CI's filings, financials, insider trades and 13F holders, then answers with sources.